« Crohn's disease: Remicade prescription to decrease, while Humira's increases | Main | Sanofi - Go East Young Man Go East! »

04/08/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0133ec8e592d970b

Listed below are links to weblogs that reference Orphan drugs to make paradigm shift in Pharma industry:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

Bruce Lehr

This is an interesting abstract from the Journal of Commercial Biotechnology that speaks to the current M&A environment in biotech industry. It passes advice on strategy small biotech's should employ in developing their product pipelines and IP, and importantly in looking at their exit strategy. The author's suggest these type of companies will continue to be attractive acquisition targets for larger companies as their pipelines dry up.
http://www.palgrave-journals.com/jcb/journal/v16/n2/abs/jcb200935a.html

Bruce Lehr

This article in the San Diego Union talks about the upsurge in Big Pharma interest in "neglected diseases" that is similar in flavor to increased interest with niche or orphan applications. Bascially, the economic winds have shifted to make it more favorable to work in these new areas.
http://www.signonsandiego.com/news/2010/apr/11/scientists-target-common-diseases/

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada